Dupilumab-Improved Lung Function Lasts in Children With Asthma

Add-on treatment with dupilumab may improve lung function in children aged 6-11 years with uncontrolled moderate to severe type 2 inflammatory asthma, results from a phase 3 study show.

Related Keywords

United States ,Houston ,Texas ,Baylor College Of Medicine ,American ,Muhammad Adrish ,Monroe Carell Jr ,Leonardb Bacharier ,Regeneron Pharmaceuticals ,Glaxosmithkline ,Drug Administration ,Cf Foundation ,American Thoracic Society International Conference ,Airways Disorders Network Steering Committee ,American College Of Chest Physicians ,Astrazeneca ,Children Hospital At Vanderbilt University Medical Center ,Monroe Carell ,Vanderbilt University Medical Center ,American College ,Chest Physicians ,Baylor College ,Disorders Network Steering Committee ,Biologics License Application ,Asthma ,Sthmatic ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Adhd ,Attention Deficit Hyperactivity Disorder ,Ttention Deficit Hyperactivity Disorder Adhd ,Attention Deficit Disorder Add ,Attention Deficit Disorder ,Odd ,Childhood Asthma ,Fev1 ,Severe Asthma ,Pulmonary Eosinophilia ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Lung ,Thoracic Region Of Chest ,Oche ,